Latest Conference Articles

Recent results from a team-based, scalable intervention to promote medication adherence highlighted that the relationship between adherence and clinical outcomes is not always clear cut, said Niteesh Choudhry, MD, PhD, associate professor at Harvard Medical School.

The outcomes in the COMPASS trial of rivaroxaban to treat patients with peripheral artery disease have been very positive, and a new analysis has looked at the cost impact of bringing the drug to market, explained Andre Lamy, MD, MHSc, FRSC, a cardiac surgeon with the Population Health Research Institute in Hamilton, Ontario, Canada.

It is important to treat addiction as a chronic disease and to address the stigmatization of both the addiction and the treatments we have available to treat it, said Dr Frank James, MD, JD, of American Society of Addiction Medicine.

The analysis presented at the American Heart Association looks strictly at healthcare costs, but a broader cost-effectiveness study is planned that will consider drug costs as well as effect on patient quality of life.

Researchers presenting at the American Heart Association look at specific populations within 2 large diabetes drug trials, CANVAS and EMPA-REG OUTCOME.

The time a patient is in a doctor's office represents a very small window of the body normally, which makes out-of-office blood pressure measurements important to confirm diagnosis of hypertension, explained Paul Whelton, MD, MSc, professor of global public health at Tulane University.

The chair of the guidelines committee said just because it's hard to change diet and exercise habits doesn't mean doctors and patients shouldn't try.

Results from higher-risk subgroups could help clinicians target this cholesterol-fighting therapy to patients who most need it, authors of one abstract say.

The EMPA-REG trial has been a big step forward for clinicians being able to put patients with type 2 diabetes onto treatment that also reduces cardiovascular disease risk, which is the primary cause of death in these patients, explained Eliot A. Brinton, MD, FAHA, FNLA, president of the Utah Lipid Center.

During a session at the 2017 Neuroscience Education Institute (NEI) Congress, Ira D. Glick, MD, professor emeritus, Department of Psychiatry and Behavioral Sciences, Stanford School of Medicine, emphasized the importance of combining psychological and psychopharmacologic strategies for patients with Axis I disorders and provided guidelines for administering the combination.

Roger S. McIntyre, MD, FRCPC, professor, Departments of Psychiatry and Pharmacology, University of Toronto, and of the Head, Mood Disorders, Psychopharmacology Unit, University Health Network, discussed the contributing factors and effects of misdiagnosing or inappropriately treating patients with antidepressants.

During a session on distinguishing between bipolar disorder and attention-deficit/hyperactivity disorder, David W. Goodman, MD, FAPA, assistant professor, Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, and director and founder, Adult Attention Deficit Disorder Center of Maryland, explained that many of the symptoms for the 2 disorders overlap.

An economic analysis presented at the 2017 Neuroscience Educational Institute (NEI) Congress in Colorado Springs, Colorado, showed that pharmacogenomic testing in patients with specific psychiatric disorders can reduce the utilization of benzodiazepines.

Christi Deaton, PhD, RN, FAHA, FESC, of the University of Cambridge discusses the necessary steps for patients to take in order to prevent cardiovascular conditions.

A panel of doctors at the 2017 Neuroscience Education Institute (NEI) Congress discussed the impact of losing a patient to suicide and how they deal with it.

At the 2017 Neuroscience Education Institute (NEI) Congress, a Friday session focused on the physiology of fear and its impact on wellness. It was presented by Mary D. Moller, PhD, DNP, ARNP, PMHCNS-BC, CPRP, FAAN, associate professor, Pacific Lutheran University School of Nursing, and director of Psychiatric Services, Northwest Center for Integrated Health.

How the president classifies the opioid epidemic matter doesn't matter as much as attention to it and dedication to responding it, said Frank James, MD, JD, of American Society of Addiction Medicine.

Exercise, diet, sleep, and hearing are 4 major factors that impact our aging, said Stephen M. Stahl, MD, PhD, adjunct professor of psychiatry, University of California San Diego during a session at the 2017 Neuroscience Educational Institute (NEI) Congress.

A session at the 2017 NEI Congress emphasized the importance of making an accurate diagnosis in patients presenting symptoms of depression.

Only 1 in 3 patients will achieve remission on their first antidepressant, and 67% of patients require 4 antidepressant trials before symptoms remit, said Thomas L. Schwartz, MD, during a session on strategies for switching, combining, or augmenting treatments for patients with major depressive disorder.

There is no known gene for any major psychiatric disorder, nor is one ever likely to be found, explained Stephan M. Stahl, MD, PhD, adjunct professor of psychiatry, University of California San Diego, during an overview of the age of personalized medicine and the role of pharmacogenetics at a session of the 2017 Neuroscience Education Institute Congress.

Digital health, artificial intelligence and machine learning, and precision medicine are the areas where there is the most excitement in innovations for cardiovascular care, said John Rumsfeld, MD, PhD, chief innovation officer at the American College of Cardiology.

In a Tuesday panel discussion at The American College of Rheumatology’s 2017 Annual Meeting in San Diego, California, representatives from HHS, the National Institutes of Health (NIH), and the CDC outlined ongoing federal initiatives to address the parallel problems of pain and opioid addiction.

On Tuesday afternoon, the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF) presented a draft of their new, jointly developed clinical guideline for treating psoriatic arthritis (PsA), at the ACR 2017 Annual Meeting.

In a Tuesday session at the American College of Rheumatology’s 2017 Annual Meeting in San Diego, California, Greg Mertz, MBA, FACMPE, managing director for Physician Strategies Group, LLC, presented a talk title “Value Contracting: Opportunities of Fantasy?” in which he outlined the current landscape for performance-based contracting.

A recap of abstracts presented at The American College of Rheumatology’s 2017 Annual Meeting, including an analysis of data available in an electronic health records database and outcomes and cost effectiveness of sarilumab.

There are a number of environmental factors with significant public health impacts that people don't necessarily think of; for instance, products out in the market haven't necesarily been tested for safety, which comsumers should keep in mind, explained Jeanette Stingone, PhD, of Mount Sinai Health System.

Kamala Nola, PharmD, MS, professor at the Lipscomb University College of Pharmacy, provided an overview of the drugs that have been approved in the past year for the treatment of inflammatory conditions during a session at the 2017 American College of Rheumatology Annual Meeting,